...
首页> 外文期刊>Advances in cancer research. >Advances in immunotherapy for prostate cancer.
【24h】

Advances in immunotherapy for prostate cancer.

机译:前列腺癌免疫治疗的进展。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Prostate cancer is the most common malignancy in American men. Metastatic prostate cancer is incurable, with the currently best treatment, androgen ablation, being only palliative. Therefore, there is a need to develop new, more effective therapies against this disease. Multiple immunotherapeutic strategies are being explored for the treatment of prostate cancer, with the hope that such treatment will be more effective and have fewer side effects than current treatment options. Several immunotherapy strategies have been shown to be effective against prostate tumors in animal models, and many of these strategies are beginning to be tested in clinical trials for their efficacy against human prostate cancer. It is likely that effective treatment of prostate cancer will require the use of both immunotherapeutic and traditional approaches in multimodality treatments. In addition, for immunotherapy to be effective against prostate cancer, ways to overcome immune evasion and immunosuppression by the tumor cells will need to be developed.
机译:前列腺癌是美国男性中最常见的恶性肿瘤。转移性前列腺癌是无法治愈的,目前只有最好的治疗方法是雄激素消融,这只是治标不治本。因此,需要开发针对该疾病的新的,更有效的疗法。目前正在探索多种免疫疗法来治疗前列腺癌,希望这种疗法比目前的治疗方法更有效,副作用更少。在动物模型中已显示出几种免疫疗法可有效对抗前列腺肿瘤,其中许多策略已开始在临床试验中测试其对抗人前列腺癌的功效。前列腺癌的有效治疗可能需要在多模态治疗中同时使用免疫治疗和传统方法。另外,为了使免疫疗法对前列腺癌有效,将需要开发克服肿瘤细胞的免疫逃避和免疫抑制的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号